- Home
- MAC vs FOLD Comparison
MAC vs FOLD Comparison
Compare MAC & FOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MAC | FOLD |
|---|---|---|
| Founded | 1964 | 2002 |
| Country | United States | United States |
| Employees | 2845 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9B | 4.5B |
| IPO Year | 1994 | 2006 |
Fundamental Metrics
Financial Performance| Metric | MAC | FOLD |
|---|---|---|
| Price | $21.59 | $14.46 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 9 |
| Target Price | $20.50 | ★ $27.25 |
| AVG Volume (30 Days) | 2.1M | ★ 2.3M |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.10% | N/A |
| EPS Growth | 11.36 | ★ 50.00 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,013,983,000.00 | N/A |
| Revenue This Year | N/A | $20.50 |
| Revenue Next Year | $4.70 | $18.59 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 10.43 | N/A |
| 52 Week Low | $14.16 | $5.66 |
| 52 Week High | $22.56 | $14.48 |
Technical Indicators
Market Signals| Indicator | MAC | FOLD |
|---|---|---|
| Relative Strength Index (RSI) | 65.04 | 64.82 |
| Support Level | $17.84 | $14.21 |
| Resistance Level | N/A | $14.48 |
| Average True Range (ATR) | 0.48 | 0.02 |
| MACD | 0.17 | -0.01 |
| Stochastic Oscillator | 72.71 | 60.00 |
Price Performance
Historical ComparisonAbout MAC Macerich Company (The)
Macerich invests in premium mall assets. The company owns 27 regional malls in its consolidated portfolio and 10 regional malls in its unconsolidated portfolio along with a power center and seven other real estate assets. The company's total portfolio has 39.9 million square feet of gross leasable area and averaged $867 sales per square foot over the 12 months ended in September 2025.
About FOLD Amicus Therapeutics Inc.
Amicus Therapeutics Inc is a biotechnology company focused to develop and deliver transformative medicines for people living with rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.